21:08 Mon 08 Jun 2020
ValiRx PLC - Correction Directorate Change & Audited accounts
The following amendment has been made to the 'Directorate Change & Audited accounts extension' announcement released on
The announcement should have stated the number of shares held by Dr
All other details remain unchanged.
The full amended text is shown below.
("ValiRx", the "Company" or the "Group")
Directorate Change and Extension of Reporting deadline for publication of audited accounts for
year to
Following her appointment, the board comprises:-
|
|
Dr |
Chief Executive Officer |
Mr |
Chief Financial Officer |
Mr |
Non-executive Director |
Mr |
Non-executive Director |
As announced on
The Company does not intend to make any further changes to the board in 2020.
Extension of deadline for publication of audited accounts to year to
Due to the current COVID-19 outbreak, the Company will be unable to post its annual audited accounts to shareholders for the year to
Further to the guidance provided by AIM Regulation in "Inside AIM" on
AIM Regulation has granted the extension, and therefore the Company will publish its annual audited accounts to
The following information is disclosed in respect of Dr
Current directorships |
Directorships and partnerships held in the past five years |
|
|
|
|
Dr
There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Dr
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
|
Tel: +44 (0) 20 7073 2628 |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
Tel: +44 (0) 20 7469 0930 |
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer.
The Company's business model focuses on identifying and in-licensing early stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.
The Company listed on the AIM Market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE